MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · Real-Time Price · USD
13.08
+0.52 (4.14%)
Nov 11, 2026, 12:04 PM EST - Market open
MLTX Stock Forecast
Stock Price Forecast
According to 16 analysts polled by S&P Global, MLTX stock has a consensus rating of "Buy" and an average price target of $30.29. The average 1-year stock price forecast is 131.57% higher than the current stock price, while the lowest is $6.00 (-54.13%) and the highest is $57 (+335.78%).
Price Target: $30.29 (+131.57%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for MLTX stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 10 | 10 | 10 | 10 | 11 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 2 | 2 | 2 | 2 | 2 | 2 |
| Total | 15 | 15 | 15 | 15 | 15 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $50 | Buy | Reiterates | $50 | +282.26% | Nov 9, 2026 |
| Chardan Capital | Chardan Capital | Buy Initiates $57 | Buy | Initiates | $57 | +335.78% | Nov 6, 2026 |
| Leerink Partners | Leerink Partners | Buy Reiterates $30 | Buy | Reiterates | $30 | +129.36% | Nov 5, 2026 |
Unknown Analyst Guggenheim No rating | Guggenheim | Buy Reiterates $40 | Buy | Reiterates | $40 | +205.81% | Nov 5, 2026 |
| BTIG | BTIG | Buy Maintains $30 | Buy | Maintains | $30 | +129.36% | Nov 5, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
20.78M
EPS This Year
-3.51
from -3.53
EPS Next Year
-3.38
from -3.51
EPS and Forward PE are based on non-GAAP adjusted numbers.